Erythropoiesis stimulating agents — epoetin alfa, darbepoetin alfa, and HIF-PHI agents — serve as the complementary therapy to iron supplementation for anemia management in conditions where iron sufficiency alone cannot correct hemoglobin, with the Iron Deficiency Anemia Therapy Market reflecting the evolving ESA and iron therapy relationship in CKD and cancer anemia management. HIF...